Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Cash Flow: 2013-2025

Historic Net Cash Flow for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $97.8 million.

  • KalVista Pharmaceuticals' Net Cash Flow fell 543.20% to -$39.0 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$21.0 million, marking a year-over-year increase of 9.80%. This contributed to the annual value of $97.8 million for FY2025, which is 521.09% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Net Cash Flow stood at $97.8 million for FY2025, which was up 521.09% from -$23.2 million recorded in FY2024.
  • KalVista Pharmaceuticals' 5-year Net Cash Flow high stood at $97.8 million for FY2025, and its period low was -$23.2 million during FY2024.
  • Its 3-year average for Net Cash Flow is $33.0 million, with a median of $24.3 million in 2023.
  • In the last 5 years, KalVista Pharmaceuticals' Net Cash Flow plummeted by 195.74% in 2024 and then spiked by 521.09% in 2025.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Net Cash Flow stood at $34.3 million in 2021, then plummeted by 154.51% to -$18.7 million in 2022, then soared by 229.83% to $24.3 million in 2023, then crashed by 195.74% to -$23.2 million in 2024, then soared by 521.09% to $97.8 million in 2025.